Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 14, 2005 - Issue 11
Submit an article Journal homepage
70
Views
43
CrossRef citations to date
0
Altmetric
Review

Clinical status of agents being developed for leishmaniasis

Jonathan Berman National Center for Complementary and Alternative Medicine, 6707 Democracy Boulevard, Suite 401, Bethesda MD 20892, USA. [email protected]
Pages 1337-1346 | Published online: 28 Oct 2005

Bibliography

  • ASHFORD RW, DESJEUX P, P: Estimation and population at risk of infection and number of cases of leishmaniasis. Parasitol Today (1992) 8:104–105.
  • ALRAJHI AA, IBRAHIM EA, VOL EB, KHAIRAT M, FARIS RM, MAGUIRE JH: Fluconazole for the treatment of cutanoues leishmaniasis caused by Leishmania major N Engl. I Med. (2002) 346:891–895.
  • HERWALDT BL, ARANA BA, NAVIN TR: The natural history of cutaneous leishmaniasis in Guatemala. J. Infect. Dis. (1992)165:518–527.
  • SOTO J, ARANA BA, TOLEDO J et al: Miltefosine for new world cutaneous leishmaniasis. Clin. Infect. Dis. (2004) 38:1266–1272.
  • SUNDAR S, JHA TK, THAKUR CP et al: Oral miltefosine for Indian visceral leishmaniasis. N Engl. J. Med. (2002) 347:1739–1746.
  • ••Phase III study demonstrating efficacy andsafety of miltefosine for Indian visceral leishmaniais.
  • SUNDAR S, ROSENKAIMER F, MAKHARIA MK et al.: Trial of oral miltefosine for visceral leishmaniasis. Lancet (1998) 352:1821–1823.
  • JHA TK, SUNDAR S, THAKUR CP et al:Miltefosine, an oral agent, for the treatment Indian visceral leishmaniasis. N Engl. J. Med. (1999) 341:1795–1800.
  • BHATTACHARYA SK, JHA TK, SUNDAR S et al: Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India. Clin. Infect. Dis. (2004) 38:217–221.
  • •Extends indication of miltefosine to childhood visceral leishmaniasis in India.
  • SINDERMANN H, ENGEL KR, FISCHER C et al: Oral miltefosine for Leishmaniasis in immunocompromised patients: compassionate use in 39 patients with HIV infection. Clin. Infect. Dis. (2004) 39:1520–1523.
  • SOTO J, ARANA BA, TOLEDO J et al.:Miltefosine for new world cutaneous leishmaniasis. Clin. Infect. Dis. (2004) 38:1266–1272.
  • HERWALDT BL: Miltefosine - the long-awaited therapy for visceral leishmaniasis? N Engl. J. Med. (1999) 341:1840–1842.
  • SHERWOOD JA, GACHIHI GS, MUIGAI RK et al: Phase II efficacy trial of an oral 8-aminoquinoline (WR6026) for treatment of visceral leishmaniasis. Clin. Infect. Dis. (1994) 19:1034–1039.
  • DIETZE R, CARVALHO SF, VALLI LC et al: Phase II trial of WR6026, an orally administered 8-aminoquinoline, in the treatment of visceral leishmaniasis caused by chagasi Am. J. Trop. Med. Hyg. (2001) 65:685–689.
  • PETTY BG, BLACK JR, HENDRIX CW et al.: Escalating multiple-dose safety and tolerance study of oral WR 6026 in HIV-infected subjects: AIDS clinical trials group 173.1 Acquir. Immune Defic. Syndr. (1999) 21:26–32.
  • RASHID JR, NYAKUNDI PM, G, KINOTI D, WASUNNA MK: Compassionate use of sitamaquine in an HIV-positive patient with visceral leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. (2002) 96:533–534.
  • BERMAN JD: Activity of imidazoles against Leishmania tropica in human macrophage cultures. Am. I Trop. Med. Hyg. (1981) 30:566–569.
  • BERMAN JD, GOAD LJ, BEACH DH, HOLZ GG Jr: Effects of ketoconazole on sterol biosynthesis by mexicana mexicana amastigotes in murine macrophage tumor cells. Biochem. Parasitol (1986) 20:85–92.
  • SAENZ RE, PAZ H, BERMAN JD: Efficacy of ketoconazole against braziliensis panamensis cutaneous leishmaniasis. Am. "Med. (1990) 89:147–155.
  • ALSALEH QA, DVORAK R, NANDA A: Ketoconazole in the treatment of cutaneous leishmaniasis in Kuwait. Int. J. Dermatol (1995) 34:495–497.
  • SINGH S, SINGH R, SUNDAR S: Failure of ketoconazole in oriental sore in India. Chemother. (1995) 7\(Suppl. 4):202–203.
  • WALI JP, AGGARWAL P, NANDY A et al: Efficacy of sodium antimony gluconate and ketoconazole in the treatment of kala-azar - a comparative study../. Commun. Dis. (1997) 29:73–83.
  • LAFFITTE E, GENTON B, RG. Cutaneous leishmaniasis by Leishmania tropica: treatment with oral fluconazole. Dermatology (2005) 210:249–251.
  • BARON S, LAUBE S, RAAFAT F, MOSS C: Cutaneous leishmaniasis in a Kosovan child treated with oral fluconazole. Clin. Exp. Dermatol. (2004) 29:546–547.
  • SUNDAR S, SINGH VP, AGRAWAL NK, GIBBS DL, MURRAY HW: Treatment of kala-azar with oral fluconazole. Lancet (1996) 348:614.
  • JHA BB: Fluconazole in visceral leishmaniasis. Indian Pediatr. (1998) 35:268–269.
  • TORRUS D, BOIX V, MASSA B, PORTILLA J, PEREZ-MATEO M: Fluconazole plus allopurinol in treatment of visceral leishmaniasis.. Chemother. (1996) 37:1042–1043.
  • SOTO-MANCIPE J, GROGL M, BERMAN JD: Evaluation of pentamidine for the treatment of cutaneous leishmaniasis in Colombia. Clin. Infect. Dis. (1993) 16:417–425.
  • CALVOPINA M, GUEVARA AG, ARMIJOS RX, HASHIGUCHI Y, DAVIDSON RN, COOPER PJ: Itraconazole in the treatment of New World mucocutaneous leishmaniasis. Int. J. Dermatol (2004) 43:659–663.
  • NASSIRI-KASHANI M, FIROOZ A, KHAMESIPOUR A et al: A randomized, double-blind, placebo-controlled clinical trial of itraconazole in the treatment of cutaneous leishmaniasis. Eur. Acad. Dermatol Venereol (2005) 19:80–83.
  • KHALIL EA, NUR NM, ZIJLSTRA EE, EL-HASSAN AM, DAVIDSON RN: Failure of a combination of two antifungal drugs, terbinafine plus itraconazole, in Sudanese post kala-azar dermal leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. (1996) 90:187–188.
  • DOGRA J, SAXENA VN: Itraconazole and leishmaniasis: a randomised double-blind trial in cutaneous disease. Int. Parasitol. (1996) 26:1413–1415.
  • MARTINEZ S, MARR JJ: Allopurinol in the treatment of American cutaneous leishmaniasis. N Engl. I Med. (1992) 326:741–744.
  • VELEZ I, AGUDELO S, HENDRICKX E et al.: Inefficacy of allopurinol as monotherapy for Colombian cutaneous leishmaniasis. A randomized, controlled. Ann. Intern. Med. (1997) 126:232–236.
  • •Large randomised trial describing the efficacy of the standard of care, allopurinol, and placebo in the New World.
  • MARTINEZ S, GONZALEZ M, VERNAZA ME: Treatment of cutaneous leishmaniasis with allopurinol and stibogluconate. OM. Infect. Dis. (1997) 24:165–169.
  • LLANOS-CUENTAS A, ECHEVARRIA J,CRUZ Metal: Efficacy of sodium stibogluconate alone and in combination with allopurinol for treatment of mucocutaneous leishmaniasis. OM. Infect. Dis. (1997) 25:677–684.
  • MOMENI AZ, AMINJAVAHERI M: Successful treatment of non-healing cases of cutaneous leishmaniasis, using a combination of meglumine antimoniate plus allopurinol. Eur. .1 Dermatol (2003) 13:40–43.
  • EL-ON J, HALEVY S, GRUNWALD MH, WEINRAUCH L: Topical treatment of Old World cutaneous leishmaniasis caused by Leishmania major a double-blind control study. J. Am. Acad. Dermatol (1992) 27:227–231.
  • SALAH A, ZAKRAOUI H, ZAATOUR A et al.: A randomized, placebo-controlled trial in Tunisia treating cutaneous leishmaniasis with paromomycin ointment. Am. J. Trop. Med. Hyg. (1995) 53:162–166.
  • ASILIAN A, JALAYER T, JA, GHASEMI RL, NILFOROOSHZADEH M, OLLIARO P: A randomized, placebo-controlled trial of a two-week regimen of aminosidine (paromomycin) ointment for treatment of cutaneous leishmaniasis in Iran. Am..! Trop. Med. Hyg. (1995) 53:648–651.
  • ASILIAN A, JALAYER T, NILFOROOSHZADEH M et al: Treatment of cutaneous leishmaniasis with aminosidine (paromomycin) ointment: double-blind, randomized trial in the Islamic Republic of Iran. Bull. World Health Organ. (2003) 81:353–359.
  • FAGHIHI G, TAVAKOLI-KIA R: Treatment of cutaneous leishmaniasis with either topical paromomycin or intralesional meglumine antimoniate.. Exp. Dermatol (2003) 28:13–16.
  • SHAZAD B, ABBASZADEH B, KHAMESIPOUR A: Comparison of topical paromomycin sulfate (twice/day) with intralesional meglumine antimoniate for the treatment of cutaneous leishmaniasis by L. major. Eur. Dermatol (2005) 15:85–87.
  • SOTO J, FUYA P, HERRERA R, BERMAN J: Topical paromomycin/ methylbenzethonium chloride plus parenteral meglumine antimonate as treatment for American cutaneous leishmaniasis: controlled study. OM. Infect. Dis. (1998) 26:56–58.
  • ARMIJOS RX, WEIGEL MM, CALVOPINA M, MANCHENO M, RODRIGUEZ R: Comparison of the effectiveness of two topical paromomycin treatments versus meglumine antimoniate for New World cutaneous leishmaniasis. Acta Trop. (2004) 91:153–160.
  • ARANA BA, MEND OZA CE, NR, KROEGER A: Randomized, controlled, double-blind trial of topical treatment of cutaneous leishmaniasis with paromomycin plus methylbenzethonium chloride ointment in Guatemala. Am. J. Trop. Med. Hyg. (2001) 65:466–470.
  • SOTO JM, TOLEDO JT, GUTIERREZ P et al.: Treatment of cutaneous leishmaniasis with a topical antileishmanial drug (WR279396): Phase II pilot study. Am. J. Trop. Med. Hyg. (2002) 66:147–151.
  • AREVALO I, WARD B, MILLER R et al: Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator. OM. Infect. Dis. (2001) 33:1847–1851.
  • MIRANDA-VERASTEGUI C, LLANOS-CUENTAS A, AREVALO I, WARD BJ, MATLASHEWSKI G: Randomized, double-blind clinical trial of topical imiquimod 5% with parenteral meglumine antimoniate in the treatment of cutaneous leishmaniasis in Peru.. Infect. Dis. (2005) 40:1395–1403
  • SEEBERGER J, DAOUD S, PAMMER J: Transient effect of topical treatment of cutaneous leishmaniasis with imiquimod. Int. J. Dermatol (2003) 42:576–579.
  • CHUNGE CN, OWATE J, PAMBA HO, DONNO L: Treatment of visceral leishmaniasis in Kenya by aminosidine alone or combined with sodium stibogluconate. Trans. R. Soc. Trop. Med. Hyg. (1990) 84:221–225.
  • •Initial clinical study of paromomycin for visceral leishmaniasis that led to the present Phase III investigations.
  • THAKUR CP, OLLIARO P, GOTHOSKAR S et al: Treatment of visceral leishmaniasis (kala-azar) with aminosidine (= paromomycin)-antimonial 1345, a pilot study in Bihar, India. Trans. R. Soc. Trop. Med. Hyg (1992) 86:615–616.
  • SEAMAN J, PRYCE D, SONDORP HE, MOODY A, BRYCESON AD, DAVIDSON RN: Epidemic visceral leishmaniasis in Sudan: a randomized trial of aminosidine plus sodium stibogluconate versus sodium stibogluconate alone.. Infect. Dis. (1993) 168:715–720.
  • JHA TK, OLLIARO P, THAKUR CP et al.: Randomized controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India. Br. Med. J. (1998) 316:1200–1205
  • THAKUR CP, KANYOK TP, AK, SINHA GP, MESSICK C, OLLIARO P: Treatment of visceral leishmaniasis with injectable paromomycin (aminosidine). An open-label randomized Phase-II clinical study. Trans. R. Soc. Trop. Med. Hyg. (2000) 94:432–433.
  • SOTO J, GROGL M, BERMAN J, OLLIARO P: Limited efficacy of injectable aminosidine as single-agent therapy for Colombian cutaneous leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. (1994) 88:695–698.
  • HEPBURN NC, TIDMAN MJ, HUNTER JA: Aminosidine (paromomycin) versus sodium stibogluconate for the treatment of cutaneous leishmaniasis. Trans R Soc Trop Med Hyg. (1994) 88:700–703.

Websites

  • http://www.who.int/leishmaniasis/burden/ en/ WHO's burden of disease information on leishmaniasis.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.